Vantage Data Points

Biopharma's least novel indications

Oncology is by far the most popular segment for novel drug development. But what about the less active areas of biopharma? The analysis below shows the number of NMEs, both marketed and clinical-stage, for each EvaluatePharma indication group, excluding those in oncology. A closer look at those indications less well served by novel therapeutics reveals a mix of classes either with a well-established generic market, or where effective targets remain elusive to the biopharma world. For our analysis of cancer's novel projects see: Oncology's haves and have-nots, July 22, 2019.

Source: EvaluatePharma Vision; data from July 2019.

Biopharma's biggest sellers – looking forward

The list of biopharma's most lucrative drugs includes some surprisingly old products that are still going strong (Biopharma's biggest sellers – the oldies that just keep giving, August 14, 2019). A look forward to the biggest drugs of the next few years reveals that some of those golden oldies are still in the top ranks. Humira and Revlimid, both over 10 years old, still feature and are forecast to sell $140bn and $70bn respectively, according to EvaluatePharma consensus.

Source: EvaluatePharma

Datapoint: Cell and gene therapy trials

The above graphic shows the number of gene and cell therapy trials for all products in clinical development or filed for approval, as listed in


For a larger/zoomable version of the image click here 

China's PD(L)-1 players

After Celgene’s return of tislelizumab rights Beigene will be looking for a new ex-China partner. The volume of work Beigene and others are already doing in China suggests the threat to US players of multiple low-cost, Asia-developed drugs.

Image can be enlarged by opening in new tab on Chrome or other browsers.

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.